Venkatakrishnareddy Yerramreddy

This inventor holds 9 USPTO granted patents, plus 3 CIPO patents and 4 EPO patents. Top assignee: Arrien Pharmaceuticals LLC. Active years: 2015-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Venkatakrishnareddy Yerramreddy. Retrieved from https://idiyas.com/inventor/venkatakrishnareddy-yerramreddy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 7(Granted Patents)

Location History:

Hyderabad, IN (US) (2015)
Hyderabad, IN (2016 - 2017)
Andhra Pradesh, IN (2016 - 2020)

Company Filing History:

9 out of 14

Arrien Pharmaceuticals LLC

patents

Years Active: 2015-2020

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10682358 - Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2020-06-16),

2. 10172866 - Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2019-01-08),

3. 9951062 - Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-04-24),

4. 9890153 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-02-13),

5. 9834551 - Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors (2017-12-05),

6. 9446047 - Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2016-09-20),

7. 9359315 - [object Object] (2016-06-07),

8. 9260426 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2016-02-16),

9. 9206188 - [object Object] (2015-12-08),

Title: Inventor Venkatakrishnareddy Yerramreddy: Innovating in Multiple Sclerosis Treatment

Introduction

Venkatakrishnareddy Yerramreddy is a notable inventor based in Andhra Pradesh, India. With a remarkable portfolio of nine patents, he has made significant contributions to the pharmaceutical industry, particularly in the development of treatments for autoimmune diseases.

Latest Patents

Among his latest innovations, Venkatakrishnareddy has pioneered compounds referred to as substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists. These compounds are designed for treating multiple sclerosis and operate as antagonists, inverse agonists, modulators, and inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt). The applications of these compounds extend beyond multiple sclerosis, targeting several disease states tied to immunopathology, including rheumatoid arthritis, inflammatory colitis, psoriasis, COPD, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases, and cancer.

Career Highlights

Currently, Venkatakrishnareddy is affiliated with Arrien Pharmaceuticals LLC, where he continues to conduct innovative research in pharmacology. His work has positioned him as a leader in the fight against autoimmune conditions, with a keen focus on enhancing the therapeutic landscape through novel compound development.

Collaborations

Throughout his career, Venkatakrishnareddy has collaborated with esteemed colleagues such as Hariprasad Vankayalapati and Rajendra P Appalaneni. These partnerships have fostered a collaborative environment aimed at pushing the boundaries of medical science and improving patient outcomes.

Conclusion

Venkatakrishnareddy Yerramreddy's contributions to the field of pharmaceuticals are commendable. His innovative patents reflect a dedication to addressing complex health challenges, particularly in autoimmune diseases. As his career progresses, he continues to inspire future inventors and researchers in the realm of medical science.

Profile summary based on public USPTO records.